GSK to pay €118 million for Intercell's travellers' diarrhoea and pandemic flu vaccines and access to patch technology
This article was originally published in Scrip
Executive Summary
Intercell of Austria and GlaxoSmithKline Biologicals are to form a strategic alliance to develop and commercialise needle-free, patch-based vaccines.